This article is more than 5 years old. Information may no longer be current.
Intracorneal inlays hold potential for emmetropic presbyopes, surgeon predicts
Click Here to Manage Email Alerts
LAS VEGAS — An emerging generation of small-diameter intracorneal inlays could be an excellent option for emmetropic presbyopes, according to a surgeon speaking here at the OSN Las Vegas meeting.
Richard L. Lindstrom, MD, Chief Medical Editor of Ocular Surgery News, presented the latest study results for small-diameter intracorneal inlay devices manufactured by Chiron/Bausch & Lomb, Biovision, Intralens and AcuFocus, which was recently purchased by Bausch & Lomb.
While each device presents a different technological spin on the concept, they have all provided promising near and distance results in small patient groups, with patients experiencing significant improvements in distance and near vision.
He said the technology behind the implants is promising for treating presbyopia in this class of patient. In the United States, there are about 62 million emmetropic presbyopes who could benefit from these technologies, he noted.
"A lot of exciting things are coming," he said. "You're going to see these products launched outside the U.S. within the next year."